Olezarsen sodium
Approved medicineAlso known as Tryngolza, olezarsen (as sodium).
Recent clinical, regulatory, research and industry developments relating to this drug.
NICE backs Sobi's Tryngolza for rare disease FCS
Indication expansion: OLEZARSEN SODIUM (NDA218614)
Marketing authorisation: Tryngolza (EMA)
Approval: OLEZARSEN SODIUM (NDA218614)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Tryngolza is indicated as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome (FCS).
Evidence ↗Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Regulatory event sources are credited in the Regulatory Timeline above.